Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...

George Lopez, Jesse Garcia and Al Madrigal are among the new additions to the one-night-only virtual table read of the 2007 ...

Highlights,Madrigal Pharmaceuticals shows strong share movement in recent weeks,Revenue growth remains uneven across short- ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 11 new ...

The world-renowned Philippine Madrigal Singers (MADZ) will take centre stage for a live performance at the Thailand Cultural ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO- ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...